Leanne Woods-Burnham1, Anamika Basu1, Christina K Cajigas-Du Ross1, Arthur Love1, Clayton Yates2, Marino De Leon1, Sourav Roy3, Carlos A Casiano1,4. 1. Department of Basic Sciences, Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California. 2. Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, Alabama. 3. Department of Entomology and Institute for Integrative Genome Biology, University of California Riverside, Riverside, California. 4. Department of Medicine, Loma Linda University School of Medicine, Loma Linda, California.
Abstract
BACKGROUND: Understanding how biological factors contribute to prostate cancer (PCa) health disparities requires mechanistic functional analysis of specific genes or pathways in pre-clinical cellular and animal models of this malignancy. The 22Rv1 human prostatic carcinoma cell line was originally derived from the parental CWR22R cell line. Although 22Rv1 has been well characterized and used in numerous mechanistic studies, no racial identifier has ever been disclosed for this cell line. In accordance with the need for racial diversity in cancer biospecimens and recent guidelines by the NIH on authentication of key biological resources, we sought to determine the ancestry of 22RV1 and authenticate previously reported racial identifications for four other PCa cell lines. METHODS: We used 29 established Ancestry Informative Marker (AIM) single nucleotide polymorphisms (SNPs) to conduct DNA ancestry analysis and assign ancestral proportions to a panel of five PCa cell lines that included 22Rv1, PC3, DU145, MDA-PCa-2b, and RC-77T/E. RESULTS: We found that 22Rv1 carries mixed genetic ancestry. The main ancestry proportions for this cell line were 0.41 West African (AFR) and 0.42 European (EUR). In addition, we verified the previously reported racial identifications for PC3 (0.73 EUR), DU145 (0.63 EUR), MDA-PCa-2b (0.73 AFR), and RC-77T/E (0.74 AFR) cell lines. CONCLUSIONS: Considering the mortality disparities associated with PCa, which disproportionately affect African American men, there remains a burden on the scientific community to diversify the availability of biospecimens, including cell lines, for mechanistic studies on potential biological mediators of these disparities. This study is beneficial by identifying another PCa cell line that carries substantial AFR ancestry. This finding may also open the door to new perspectives on previously published studies using this cell line.
BACKGROUND: Understanding how biological factors contribute to prostate cancer (PCa) health disparities requires mechanistic functional analysis of specific genes or pathways in pre-clinical cellular and animal models of this malignancy. The 22Rv1 human prostatic carcinoma cell line was originally derived from the parental CWR22R cell line. Although 22Rv1 has been well characterized and used in numerous mechanistic studies, no racial identifier has ever been disclosed for this cell line. In accordance with the need for racial diversity in cancer biospecimens and recent guidelines by the NIH on authentication of key biological resources, we sought to determine the ancestry of 22RV1 and authenticate previously reported racial identifications for four other PCa cell lines. METHODS: We used 29 established Ancestry Informative Marker (AIM) single nucleotide polymorphisms (SNPs) to conduct DNA ancestry analysis and assign ancestral proportions to a panel of five PCa cell lines that included 22Rv1, PC3, DU145, MDA-PCa-2b, and RC-77T/E. RESULTS: We found that 22Rv1 carries mixed genetic ancestry. The main ancestry proportions for this cell line were 0.41 West African (AFR) and 0.42 European (EUR). In addition, we verified the previously reported racial identifications for PC3 (0.73 EUR), DU145 (0.63 EUR), MDA-PCa-2b (0.73 AFR), and RC-77T/E (0.74 AFR) cell lines. CONCLUSIONS: Considering the mortality disparities associated with PCa, which disproportionately affect African American men, there remains a burden on the scientific community to diversify the availability of biospecimens, including cell lines, for mechanistic studies on potential biological mediators of these disparities. This study is beneficial by identifying another PCa cell line that carries substantial AFR ancestry. This finding may also open the door to new perspectives on previously published studies using this cell line.
Authors: Xianyun Mao; Abigail W Bigham; Rui Mei; Gerardo Gutierrez; Ken M Weiss; Tom D Brutsaert; Fabiola Leon-Velarde; Lorna G Moore; Enrique Vargas; Paul M McKeigue; Mark D Shriver; Esteban J Parra Journal: Am J Hum Genet Date: 2007-04-20 Impact factor: 11.025
Authors: M M Webber; S T Quader; H K Kleinman; D Bello-DeOcampo; P D Storto; G Bice; W DeMendonca-Calaca; D E Williams Journal: Prostate Date: 2001-04 Impact factor: 4.104
Authors: K A Klein; R E Reiter; J Redula; H Moradi; X L Zhu; A R Brothman; D J Lamb; M Marcelli; A Belldegrun; O N Witte; C L Sawyers Journal: Nat Med Date: 1997-04 Impact factor: 53.440
Authors: Nao Hagiwara; Lisa Berry-Bobovski; Carie Francis; Lauren Ramsey; Robert A Chapman; Terrance L Albrecht Journal: J Cancer Educ Date: 2014-09 Impact factor: 2.037
Authors: Roble G Bedolla; Dimpy P Shah; Shih-Bo Huang; Robert L Reddick; Rita Ghosh; Addanki P Kumar Journal: Mol Carcinog Date: 2019-03-11 Impact factor: 4.784
Authors: Stanley E Hooker; Leanne Woods-Burnham; K Sean Kimbro; Rick A Kittles; Madhavi Bathina; Stacy Lloyd; Priyatham Gorjala; Ranjana Mitra; Larisa Nonn Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-20 Impact factor: 4.254
Authors: Elio Mazzone; Marco Bandini; Felix Preisser; Sebastiano Nazzani; Zhe Tian; Firas Abdollah; Denis Soulieres; Markus Graefen; Francesco Montorsi; Shahrokh Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2019-06 Impact factor: 1.862
Authors: Michael D Kessler; Nicholas W Bateman; Thomas P Conrads; George L Maxwell; Julie C Dunning Hotopp; Timothy D O'Connor Journal: Cancer Date: 2019-03-13 Impact factor: 6.860